Method for increasing permeability of blood-brain barrier

1. A method for increasing the blood-brain barrier permeability, the method comprising:

(S1) a step of delivering a nanogenerator wherein the nanogenerator includes barium titanate (BaTiO 3 ) particles and a polydopamine layer covering the surface of the barium titanate particles carrying a nitric oxide (NO) donor wherein the nitric oxide donor is an ultrasound-responsive nitric oxide donor and is N,N′-di-sec-butyl-N,N′-dinitroso-1,4-phenylenediamine (BNN6, C 14 H 22 N 4 O 2 ) to a site adjacent to the blood-brain barrier;

(S2) a step of delivering a first triggering stimulus wherein the first triggering stimulus is ultrasound to an area where the nanogenerator has been delivered so as to release nitric oxide from the nanogenerator; and

(S3) a step of allowing the released nitric oxide to activate matrix metallopeptidase-9 (MMP-9) and inducing the activated MMP-9 to weaken the tight junction between a cerebrovascular endothelial cell and another cerebrovascular endothelial cell.

2. The method for increasing the blood-brain barrier permeability according to claim 1 , wherein the ultrasound is an ultrasound with a center frequency of 1.0 to 1.5 MHz and a duty cycle of 10% to 20%.

3. The method for increasing the blood brain barrier permeability according to claim 1 , wherein in the step (S1), an active agent is delivered together with the nanogenerator to a site adjacent to the blood-brain barrier.

4. The method for increasing the blood-brain barrier permeability according to claim 3 , wherein the active agent is a small molecule, a protein, a polysaccharide, a nucleic acid, a lipid, or a mixture of any two or more of these.

5. The method for increasing the blood-brain barrier permeability according to claim 3 , wherein the active agent is a pharmaceutically active agent, a diagnostically active agent, or a combination of these.

6. The method for increasing the blood-brain barrier permeability according to claim 5 , wherein the pharmaceutically active agent is a drug, a neurotrophic factor or a growth factor for treating any one or more diseases selected from the group consisting of a neurodegenerative disease, a neuropsychiatric disease, a brain tumor, a traumatic brain injury and a stroke.

7. The method for increasing the blood-brain barrier permeability according to claim 1 , further comprising:

(S4) a step of allowing the nanogenerator to be delivered to the deep part of the brain by passing through between a cerebrovascular endothelial cell and a cerebrovascular endothelial cell, the step being performed after the step (S3); and

(S5) a step of delivering a second triggering stimulus to the nanogenerator that has been delivered to the deep part of the brain, so as to open the Ca 2+ influx channels of neurons present around the nanogenerator through a piezoelectric effect of the nanogenerator.

8. The method for increasing the blood-brain barrier permeability according to claim 7 , wherein the second triggering stimulus is any one or more selected from the group consisting of ultrasound, sound, mechanical pressure, and resonance.

9. The method for increasing the blood-brain barrier permeability according to claim 7 , wherein the method is used for alleviating the symptoms of a degenerative brain disease.